Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anja Potthoff

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Plos One|May 3, 2011
Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disordersAiden Haghikia, Moritz Perrech, Bartosz Pula, et al.
AIDS (London, England)|January 20, 2026
Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1Christoph Wyen, Celia Jonsson-Oldenbüttel, Sebastian Noe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 17, 2022
S1-Leitlinie: Kaposi-SarkomStefan Esser, Helmut Schöfer, Christian Hoffmann, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 3, 2022
S1 Guidelines for the Kaposi SarcomaStefan Esser, Helmut Schöfer, Christian Hoffmann, et al.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b studySamit R Joshi, Ezequiel Cordova, Essack Mitha, et al.
Frontiers in Immunology|December 19, 2022
Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIVClara Bessen, Carlos Plaza-Sirvent, Agit Simsek, et al.
European Journal of Medical Research|August 2, 2007
Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART studyTill Neumann, Stefan Esser, Anja Potthoff, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 29, 2015
S2k guideline* "Diagnosis and therapy of syphilis"--short versionHelmut Schöfer, Tobias Weberschock, Wolfgang Bräuninger, et al.
Pharmacological Research|October 18, 2025
Safety and efficacy of monoclonal antibody therapy in patients with chronic herpes simplex virus-2 genital infections: MATCH-2, a randomized double-blinded, parallel-group phase 2 multi-center trialHans-Jürgen Stellbrink, Torsten Schaller, Kerstin Sturm, et al.
The Lancet. Infectious Diseases|March 21, 2025
Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort studyDavid Hillus, Ngoc Han Le, Pinkus Tober-Lau, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Plos One|May 3, 2011
Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disordersAiden Haghikia, Moritz Perrech, Bartosz Pula, et al.
AIDS (London, England)|January 20, 2026
Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1Christoph Wyen, Celia Jonsson-Oldenbüttel, Sebastian Noe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 17, 2022
S1-Leitlinie: Kaposi-SarkomStefan Esser, Helmut Schöfer, Christian Hoffmann, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 3, 2022
S1 Guidelines for the Kaposi SarcomaStefan Esser, Helmut Schöfer, Christian Hoffmann, et al.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b studySamit R Joshi, Ezequiel Cordova, Essack Mitha, et al.
Frontiers in Immunology|December 19, 2022
Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIVClara Bessen, Carlos Plaza-Sirvent, Agit Simsek, et al.
European Journal of Medical Research|August 2, 2007
Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART studyTill Neumann, Stefan Esser, Anja Potthoff, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 29, 2015
S2k guideline* "Diagnosis and therapy of syphilis"--short versionHelmut Schöfer, Tobias Weberschock, Wolfgang Bräuninger, et al.
Pharmacological Research|October 18, 2025
Safety and efficacy of monoclonal antibody therapy in patients with chronic herpes simplex virus-2 genital infections: MATCH-2, a randomized double-blinded, parallel-group phase 2 multi-center trialHans-Jürgen Stellbrink, Torsten Schaller, Kerstin Sturm, et al.
The Lancet. Infectious Diseases|March 21, 2025
Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort studyDavid Hillus, Ngoc Han Le, Pinkus Tober-Lau, et al.
Pageof 7